Tim Franklin, ImmuPharma’s Chief Operating Officer talks to Proactive Investor on the forthcoming meeting in December between the Company’s partner Avion and the FDA, to discuss the international Phase 3 Lupus clinical trial – 25th November 2020

Dr Franklin says at the meeting, Avion together with the FDA will discuss key points and following the meeting the FDA will respond giving their guidance. He says a conditional approval would allow the marketing of Lupuzor™ prior to the completion of the new Phase 3, based on the clinically significant data previously generated in the completed Phase 2 and 3 clinical trials to date.